iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmac - TulsaCW.com: TV To Talk About | The Tulsa CW

iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. 

iRobot Corporation (NASDAQ: IRBT)
Class Period: November 21, 2016 - October 22, 2019
Deadline: December 23, 2019
For more info:www.bgandg.com/irbt
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:  (1) iRobot’s explosive growth was not based on increased demand, expanding margins, and product innovations, as it claimed, but rather based on channel stuffing; (2) the Company attempted to conceal its actions by acquiring its distributors in Europe and Asia; (3) these acquisitions were designed to clean up the company’s global inventory and mask falling demand; and (4) as a result, iRobot’s public statements were materially false and misleading at all relevant times.

Zendesk, Inc. (NASDAQ: ZEN)
Class Period: February 6, 2019 - October 1, 2019
Deadline: December 23, 2019
For more info:www.bgandg.com/zen
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zendesk's clients had been subject to data breaches dating back to 2016; (2) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the U.K. and Australia, due in large part to political uncertainty and China trade issues; (3) for the forgoing reasons, Zendesk's business metrics and financial prospects were not as strong as represented during the Class Period; and (4) as a result, Zendesk's public statements were materially false and misleading at all relevant times. 

Zynerba Pharmaceuticals, Inc.(NASDAQ: ZYNE)
Class Period: March 11, 2019 - September 17, 2019
Deadline: December 23, 2019
For more info:www.bgandg.com/zyne   
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Primary Logo

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection there with. If you are affiliated with this page and would like it removed please contact pressreleases@franklymedia.com

Powered by Frankly
All content © Copyright 2000 - 2020 KQCW. All Rights Reserved.
For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.